Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene Symbol | ABL1 | ||||||||||
Synonyms | ABL | BCR-ABL | bcr/abl | c-ABL | c-ABL1 | CHDSKM | JTK7 | p150 | v-abl | ||||||||||
Gene Description | ABL1, ABL proto-oncogene 1, non-receptor tyrosine kinase, plays a role in regulation of cell growth through ERK5, Rac/JNK, and Stat1/3 pathways (PMID: 10373409). Fusion proteins of BCR-ABL1 resulting in constitutive kinase activity have been reported in various cancers (PMID: 18851712, PMID: 30125955) and a number of Abl1 mutations in the context of BCR-ABL1 have been demonstrated to confer drug resistance (PMID: 24456693). | ||||||||||
|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04793399 | Phase Ib/II | Atezolizumab + Bosutinib | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | Terminated | ESP | 0 |
NCT03874858 | Phase II | Nilotinib Asciminib + Nilotinib | De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE) | Active, not recruiting | ITA | 0 |
NCT04160546 | Phase II | Aspirin + Ponatinib | Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) (ResToP) | Active, not recruiting | ESP | 0 |
NCT01593254 | Phase II | Imatinib Dasatinib | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN) | Completed | USA | ITA | FRA | ESP | CAN | BEL | AUT | 8 |
NCT02730195 | Phase II | Pioglitazone | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia | Terminated | USA | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT03375307 | Phase II | Olaparib | Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | Recruiting | USA | 0 |
NCT02767063 | Phase Ib/II | Avelumab Pioglitazone | Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW) | Unknown status | FRA | 0 |
NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus) | Recruiting | FRA | 0 |
NCT02538926 | Phase II | Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Withdrawn | USA | 0 |
NCT04501614 | Phase Ib/II | Ponatinib | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | AUS | 8 |
NCT02272998 | Phase II | Ponatinib | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | Active, not recruiting | USA | 0 |
NCT06163430 | Phase I | TERN-701 | CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | Not yet recruiting | USA | 0 |
NCT02782403 | Phase Ib/II | Axitinib + Bosutinib | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | Terminated | USA | 0 |
NCT02629692 | Phase Ib/II | K0706 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies | Active, not recruiting | USA | ITA | GBR | FRA | ESP | BEL | 6 |
NCT05384587 | Phase II | Asciminib | Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE) | Recruiting | USA | 0 |
NCT03106779 | Phase III | Bosutinib Asciminib | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 16 |
NCT02311998 | Phase Ib/II | Bosutinib + Inotuzumab ozogamicin | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | Completed | USA | 0 |
NCT04835584 | Phase Ib/II | Dasatinib + KRT-232 KRT-232 + Nilotinib | KRT-232 and TKI Study in Chronic Myeloid Leukemia | Recruiting | USA | ITA | FRA | ESP | CAN | 3 |
NCT02228382 | FDA approved | Bosutinib | Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors | Terminated | USA | ITA | FRA | ESP | DEU | AUT | 2 |
NCT04329325 | Phase II | Dasatinib + Dexamethasone + Methotrexate Blinatumomab + Dasatinib + Methotrexate | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT06236724 | Phase II | Asciminib | Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | Recruiting | USA | 0 |
NCT01744665 | Phase II | Nilotinib | Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5. (ENESTgoal) | Completed | USA | 0 |
NCT03595917 | Phase I | Asciminib + Blinatumomab + Dasatinib + Prednisone | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | Recruiting | USA | 0 |
NCT02081378 | Phase I | Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib | A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL | Completed | USA | NLD | ITA | FRA | ESP | DEU | AUS | 3 |
NCT04925479 | Phase Ib/II | Asciminib | Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Recruiting | USA | NLD | ITA | FRA | DEU | 9 |
NCT05751044 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Venetoclax | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B) | Not yet recruiting | NLD | 0 |